SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
Rhea-AI Summary
SeaStar Medical Holding (Nasdaq: ICU), a commercial-stage healthcare company specializing in treatments for critically ill patients with organ failure, has scheduled its fourth quarter and year-end 2024 financial results announcement for March 27, 2025, after market close.
The company will host a webcast and conference call to discuss the results and business progress. A replay will be available until April 3, 2025, accessible via webcast or by calling 1 (609) 800-9909.
Positive
- None.
Negative
- None.
News Market Reaction – ICU
On the day this news was published, ICU gained 1.38%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress.
| Date/Time: | Thursday, March 27, at 4:30 p.m. ET / 1:30 p.m. PT |
| Webcast: | The live webcast and replay can be found here. |
| Conference ID: | 2078693 |
| Dial-in numbers: | 1 (800) 715-9871 within the U.S. |
| 1 (646) 307-1963 from outside the U.S. | |
A replay of the call will be available after 7:30 pm ET and can be accessed as follows:
- The webcast replay is available here.
- The call replay number is 1 (609) 800-9909 and will be available through April 3, 2025.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for four therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
FAQ
When will SeaStar Medical (ICU) release its Q4 and full-year 2024 earnings?
How can investors access SeaStar Medical's (ICU) Q4 2024 earnings call replay?
Until what date will SeaStar Medical's (ICU) Q4 2024 earnings call replay be available?
What is SeaStar Medical's (ICU) primary business focus?
